

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

February 24, 2021

Todd Patrick Chief Executive Officer Armata Pharmaceuticals, Inc. 4503 Glencoe Avenue Marina del Rey, CA

> Re: Armata Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed February 9, 2021 File No. 001-37544

Dear Mr. Patrick:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Faith Charles